Stop making this handwashing mistake, eat shrimp and use the Pomodoro technique to clean up — plus 8 more tips to improve your health
Hello Yahoo Life readers! My name is Kaitlin Reilly, and I am here to share the best health and wellness tips from around the internet.
This week, Kerry Justich spoke to American track and field Olympian Gabby Thomas, who spilled her wellness routine. This includes drinking coffee, which Thomas says is 'one of the first things I do every morning.'
The athlete may not be ditching coffee anytime soon, but plenty of people are, whether that's due to caffeine jitters or digestive woes. The good news? There are some excellent coffee alternatives on the market.
This week, I explored whether beanless brews and coffee blends — some of which are made with mushrooms or upcycled ingredients like date pits — are a good solution for when you're craving a pick-me-up that isn't a traditional cup of joe. While experts say there's no reason to ditch coffee if your body responds well to it, you could get some perks by sipping on these beverages, such as a brain boost from adaptogens like reishi.
Take a peek at the local weather forecast and, if so inclined, peruse your horoscope to see what the stars have in store. Then check out what small steps you can take to make the week ahead great.
The National Foundation for Infectious Diseases just released its State of Handwashing report, which revealed that 48% of Americans are not washing their hands at key times. But some may not be aware of what those times even are. For example, while most Americans sudsed up after going to the bathroom and handling food (phew!), the NFID says that we should also be washing our hands after visiting food-centric places — like a grocery store, restaurant or coffee shop — as well as the doctor's office, pharmacy or hospital. These places have the potential to be particularly germy, and those germs can go from your hands into your mouth, eyes or nose and get you sick.
An easy habit to stick with? Wash your hands every time you come home, and make sure you're doing it the right way: Scrub with soap and water for at least 20 seconds, making sure to get under your fingernails. Don't forget to properly dry your hands too; wet hands spread germs more easily.
May 10 is National Shrimp Day, but there are a lot of reasons to eat this crustacean year-round. One big benefit of shrimp is that it's very low in calories while also being high in protein — a three-ounce serving has about 20 grams of protein. Plus, it also contains minerals like potassium, phosphorus and magnesium.
Want to get the best-tasting shrimp? While it may make dinner take a little longer to prepare due to the de-shelling process, buying shrimp that are still in their shells will deepen that umami flavor.
It's already May, and you still haven't gotten around to spring cleaning? It's time to stop procrastinating. Yes, organizing your closets and filing 6 months' worth of random paperwork can feel overwhelming, but Apartment Therapy has a handy hack: Try cleaning with the Pomodoro technique, a method in which you work in focused 25-minute intervals followed by five-minute breaks. The goal? Staying motivated while also breaking down big tasks into smaller, more manageable chunks. Your house will get clean and you won't lose your mind in the process — a win-win!
Weird … but kind of genius? A writer at Salon found that her smoothies tasted even better when she started using roasted fruit. Think roasting peaches with honey and cinnamon, or creating an apple pie-inspired smoothie by baking apples, storing them in the fridge overnight and then blending them with rolled oats in the a.m. It's a great way to make a morning smoothie way more exciting with new flavors.
The latest fitness craze on social media? People doing 100 kettlebell swings a day. You don't need to do that many reps to enjoy the benefits of this exercise, however.
'Most of us spend a lot of time sitting — on our phones, at our computers, in our cars — which makes the front of our body super-tight and pulls us into that rounded, hunchback position,' personal trainer Nico Gonzalez tells Yahoo Life. 'When done correctly, kettlebell swings really activate the muscles along your spine, the backs of your arms and the backs of your legs, which helps bring your posture upright. So, it's actually a really great corrective exercise.'
Research says that working out with kettlebells can improve your grip and muscle strength overall, as well as lower inflammation. This week, make your gym workout all about kettlebells with this five-move kettlebell plan.
I recently hit up an infrared sauna on my longevity treatment journey and was so glad I did; there's nothing more relaxing than getting a good sweat in. But there's science behind the sweat too: Regularly using a sauna has been shown to reduce joint and muscle stiffness, improve your immune system and enhance sleep. Plus, spending time in a sauna has also been linked to a better mood. I, for one, am never happier.
Try sitting in a sauna for 15 to 20 minutes, Dr. Jaclyn Tolentino, a primary care physician at Love.Life, tells Women's Health. If you feel dizzy or sick, step out. "Sauna use should feel like a supportive ritual, not a challenge to power through,' Tolentino explains. "The key is to listen to your body — it should feel nourishing, not punishing."
Gossiping has an admittedly bad reputation. But there's actually some good that can come from talking about others. 'Human connection through shared information and communication is core to who we are and connects us to each other,' Thea Gallagher, director of wellness programs at NYU Langone Health, tells Fox News. 'We might feel closer to someone when we know they are confiding in us with information and vice versa.'
And gossiping can also build empathy. For example, if you get wind that someone else is dealing with something (divorce, a sick parent, etc.) you can relate to, you may feel more connected to that person and be even more likely to open up to them in the future.
The key to making sure gossip never becomes malicious or catty is to ensure it's coming from a place of curiosity, rather than to harm someone's reputation through the spread of mean-spirited comments.
May 11 is National Foam Rolling Day, which should be your reminder to break out your roller after an intense exercise session. Foam rolling is a practice in which you use a foam cylinder (or sometimes even something spherical, like a hard rubber ball) to apply pressure to sore or tight muscles. This targets fascia, aka the connective tissue surrounding muscles and organs. It helps increase blood flow, reduce muscle tension and improve flexibility, making it an excellent way to aid in recovery, not to mention prevent injury next time you work out.
Need help getting started? Try these two easy exercises from Men's Fitness. And make sure to skip foam rolling your neck, joint areas or anywhere that you're already injured; you could do more harm than good.
In the mood to try a new tea? Try dandelion tea — especially if you deal with digestive discomfort. Dandelion tea can help relieve bloating, which can potentially come from eating a high-sodium diet, thanks to its natural diuretic properties, helping to flush excess fluid from the body.
But that's not the only reason to try this herbal tea: Dandelion tea is packed with antioxidants, including beta-carotene, in addition to being a good source of vitamin A.
You may have seen the 'okra water' trend making its rounds on TikTok, with some claiming that this drink — which is made by soaking sliced raw okra pods overnight and straining out the solids — helps with blood sugar control. While there haven't been studies confirming this, there is still a good reason to eat okra, which is packed with fiber, minerals and antioxidants. It's specifically a great source of magnesium and folate, which support muscle and heart health. Try pickling it, using shorter pods and patting them dry before brining to avoid a slimy texture.
Resistance training is so important for maintaining muscle mass and bone health. This week, change things up by picking up a medicine ball. Training with a medicine ball helps build 'explosive power, increases body strength, increases speed and provides more versatile movement in different planes,' fitness coach Tatiana Lampa tells Women's Health.
You can slam a medicine ball, toss it or twist with it beyond what you could do with a traditional weight. Plus, the shape and feel of a medicine ball means it mimics real-world activities — like, say, lifting a toddler or carrying a bag of groceries — which helps build functional strength.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
18 minutes ago
- Associated Press
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer – NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE: PFE), for vepdegestrant for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This submission is based on results from VERITAC-2 (NCT05654623), a global, randomized Phase 3 trial evaluating vepdegestrant versus fulvestrant. 'This milestone comes after an exciting presentation at the American Society of Clinical Oncology's annual meeting,' said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas. 'We look forward to the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option.' Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with advanced or metastatic ER+/HER2- breast cancer and was granted fast track designation as a monotherapy by the FDA. Results from the VERITAC-2 study were recently presented in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting and were selected for the ASCO press briefing and for Best of ASCO. Detailed results were also simultaneously published in the New England Journal of Medicine. About the VERITAC-2 Clinical Trial The Phase 3 VERITAC-2 clinical trial ( NCT05654623 ) is a global, randomized trial evaluating the efficacy and safety of vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The trial enrolled 624 patients at sites in 25 countries who had previously received treatment with a CDK4/6 inhibitor plus endocrine therapy. Patients were randomized 1:1 to receive either vepdegestrant once daily, orally on a 28-day continuous dosing schedule, or fulvestrant, administered intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each 28-day cycle starting from Day 1 of Cycle 2. In the trial, 43% of patients (n=270) had ESR1 mutations detected. The primary endpoint was progression-free survival (PFS) in the ESR1-mutation and intent-to-treat populations as determined by blinded independent central review. Overall survival is the key secondary endpoint. About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER). Vepdegestrant is being developed as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting. In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy. About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit and connect on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option; and vepdegestrant's development as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations in the second line-plus setting. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'target,' 'goal,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'look forward,' 'continue,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration between Arvinas and Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant as a monotherapy; whether the VERITAC-2 clinical trial will meet the secondary endpoint for overall survival; risks related to our expectations regarding the potential clinical benefit of vepdegestrant to patients; uncertainties relating to regulatory applications and related filing and approval timelines, including the New Drug Application seeking FDA approval of vepdegestrant and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; whether FDA or other regulatory authorities will require additional information or further studies, or may fail or refuse to approve or may delay approval of vepdegestrant; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all; Arvinas' ability to protect its intellectual property portfolio; Arvinas' reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas' cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the 'Risk Factors' section of Arvinas' Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas' current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date subsequent to the date of this release. Contacts Investors: Jeff Boyle +1 (347) 247-5089 [email protected] Media: Kirsten Owens +1 (203) 584-0307 [email protected]


New York Times
43 minutes ago
- New York Times
Our New Podcast
Health care for transgender youths is deeply personal and important to thousands of American families. It's also one of the most divisive cultural and political issues of our time. Twenty-seven states have banned surgery, hormone treatments or puberty blockers for minors. The Supreme Court will decide soon whether those bans are constitutional. The Times just published a special six-part podcast on the history of these treatments and the contentious debate. It reflects two years of work by Azeen Ghorayshi, who has reported on the intersection of gender and science for a decade, and Austin Mitchell, a senior audio producer. Jodi, who oversees Times newsletters, spoke to Azeen about the project's ambition, how she got people to open up, the biggest surprises in the reporting and how her own work has been weaponized. How was this project different from your prior work on this beat? What were the big unanswered questions you set out to explore? With this audio series, the interviews are more like long, in-depth conversations. People can connect more easily when they hear others in this way, and it can help challenge assumptions. The big question we were trying to answer was, How did we get here? The science and the politics have gotten so entangled, but something this reporting made clear is that politics has been baked in all along. The show is titled 'The Protocol,' after the Dutch Protocol, which grew out of the pioneering treatments in the Netherlands in the 1990s and 2000s. Why start there? Want all of The Times? Subscribe.
Yahoo
an hour ago
- Yahoo
Trump's new budget bill hides an assault on hospice
President Trump's 'big beautiful bill,' which passed the House with almost unanimous Republican support on May 22, mandates $500 billion in cuts to Medicare. This is a cruel assault on some of the most vulnerable Americans that will strip them of vital health care services. It will also take an axe to hospice, which relies on Medicare reimbursement to function. Since 1982, when Medicare first began covering hospice, Americans have turned to it for essential end-of-life services that address the specialized needs of the dying and allow for death with dignity. Our current system doesn't always run perfectly and would benefit from greater funding and support. I know this because when my mother was 99.5 years of age and less than six months away from her death, medical staff at our local hospice agency determined she was not, in fact, dying soon enough. Presumably adhering to Medicare guidelines, they callously discontinued our hospice services. The abrupt cessation of care prompted my debilitated mom's eviction from an assisted living facility. The chaotic aftermath necessitated medicine, schedule and equipment adjustments for her and delivered a massive blow to me, her primary caregiver. Fewer resources means this financially draining and emotionally wrenching situation will become more common — perhaps even the norm. The shifting demographics make the picture even bleaker. The U.S. is a rapidly aging population, with the number of Americans ages 65 and older expected to more than double over the next 40 years. At a time when we should be buttressing hospice services, our government is threatening to starve them. According to the Office of the Inspector General, 'About 1.7 million Medicare beneficiaries receive hospice care each year, and Medicare pays about $23 billion annually for this care.' Hospice is an interdisciplinary service that provides everything from pain relief to spiritual support to medication management to dietary consulting to mobility equipment to bereavement counseling. While the price tag may sound hefty and our current administration would like us to believe that public services are an unbearable financial burden, an investigation published in the Journal of American Medical Association Health Forum found that hospice saves Medicare money. Research shows that hospice significantly benefits dementia and cancer patients at the end of their lives. On May 19, 2025, the Journal of the American Geriatrics Society published a study of 51,300 assisted living residents that concluded, 'Higher frequency of hospice staff visits was associated with better perceived hospice quality. Policies supporting greater hospice staff engagement, including nonclinical staff, may enhance end-of-life care experiences for assisted living residents.' The report matters because the findings illuminate the humane need for both clinical and nonclinical treatment that provides for medical and emotional support as life ends. We all heard President Trump campaign on promises to protect Medicare, but Richard Fiesta, executive director of the advocacy group Alliance for Retired Americans, describes the ongoing national budget scene as 'an all-out assault on Medicare and Medicaid that will hurt older Americans in every community across the country.' And Shannon Benton, the executive director of the Senior Citizens League, another advocacy group, now warns that the potential Medicare cuts could lead to lower reimbursement rates. This would be disastrous for millions of Americans and would threaten to eradicate end-of-life care as we know common belief, hospices are not run by volunteers. Volunteers might become part-time visitors or assistants for a variety of tasks, but hospice administrations are led by professionals who are evaluated on financial performance and organizational viability. Palliative care is free to recipients and families and available at all income levels, but hospices are businesses, and they must raise sufficient funds through donations, gifts, bequests and reimbursements to compensate employees, repay loans, cover operating costs, and plan for exigencies. Simply put, much of that money comes from Medicare. Specialized care for the dying was introduced to the U.S. in 1963, when Yale University's then dean Florence Wald invited Dame Cicely Saunders of the U.K. to participate in a visiting lecture at Yale. At that time Saunders said, 'We will do all we can not only to help you die peacefully, but also to live until you die.' Four years later, in 1967, Saunders created St. Christopher's Hospice in the U.K. Later, in 1974, Florence Wald founded Connecticut Hospice in Branford, Connecticut — America's first hospice. Within five years and after several national conferences, the U.S. Department of Health, Education and Welfare acknowledged that hospices provided alternative care programs for Americans losing their lives to terminal illnesses. Federal hospice regulations were drafted. In 1982, Medicare added hospice care to its benefits, and in 1985, Medicare hospice coverage became permanent. With that, the U.S. recognized the right of its citizens to die with dignity. Forty years later, our government has signaled that a rollback of that right may be on the horizon. Eventually, my mother died in a highly regarded long-term care complex without hospice support and with no prescribed opioids. It was an unnecessarily excruciating death that exacerbated my and my family's grief. The trauma we suffered was destabilizing and healing from it was slow and difficult. If Trump's Orwellian-named 'big beautiful bill' passes the Senate, I fear our experience will have been an ugly preview of what is to come.